NTC accelerates MDR transition, certifying 65% of its medical device portfolio

Milan, 24/02/2026 – NTC S.r.l. (NTC), An international pharmaceutical company headquartered in Italy, with a strong focus on ophthalmology and a significant presence in gynecology and gastroenterology, announces that 20 medical devices have successfully obtained MDR certification, with 12 additional devices currently under assessment by the Notified Body and 5 more scheduled for submission.

Among the MDR-certified products is also the eye drop HA 0.4% without phosphates from the Imperial line, in Iridya™, the innovative preservative-free multidose device, characterized by exceptional drop control for precise dosing, an elongated tip for greater accuracy in instillation, and advanced ergonomics to assure a low squeeze force bottle.

“The MDR requirements have driven us to further strengthen the value of our portfolio,” said Riccardo Carbucicchio, CEO of NTC. “This achievement secures long-term market access and reinforces the trust of our partners.” This milestone ensures the continued availability of high-quality medical technologies and safeguards NTC’s broad medical device portfolio across the European market.

The MDR transition is a key step to ensure continuity, reliability, and patient safety. With a structured roadmap extending through 2027, NTC is well-positioned to complete its MDR transition, a key step to ensure continuity, reliability, and patient safety.

About NTC
A pharmaceutical company headquartered in Milan - Italy, with distributors and partners in more than 100 countries, engaged in research, development, registration, and commercialization of drugs, medical devices, and food supplements in ophthalmology, and other therapeutic areas including pediatrics, gynecology, and gastroenterology. NTC offers more than 250 partners innovative and high quality standard pharmaceutical products. For more information, please visit www.ntcpharma.com